1. Home
  2. PHVS vs CPRI Comparison

PHVS vs CPRI Comparison

Compare PHVS & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$33.24

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

N/A

Current Price

$21.58

Market Cap

2.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
PHVS
CPRI
Founded
2015
1981
Country
Switzerland
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
PHVS
CPRI
Price
$33.24
$21.58
Analyst Decision
Strong Buy
Buy
Analyst Count
14
15
Target Price
★ $57.68
$23.17
AVG Volume (30 Days)
612.3K
★ 3.5M
Earning Date
11-24-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.40
EPS
N/A
★ 0.85
Revenue
N/A
★ $3,474,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.45
P/E Ratio
★ N/A
$25.29
Revenue Growth
★ N/A
N/A
52 Week Low
$22.78
$12.40
52 Week High
$43.25
$28.27

Technical Indicators

Market Signals
Indicator
PHVS
CPRI
Relative Strength Index (RSI) 53.10 77.38
Support Level $32.26 $16.82
Resistance Level $36.36 $21.98
Average True Range (ATR) 1.49 0.83
MACD 0.30 0.46
Stochastic Oscillator 63.23 96.87

Price Performance

Historical Comparison
PHVS
CPRI

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 600 company-owned stores, wholesale partners, and online. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold through third-party retailers, e-commerce platforms, and in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

Share on Social Networks: